MedTrace Logo

Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients

NCT05518929 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1090

Last updated 2024-06-07

No results posted yet for this study

Summary

Ciprofol is a new general anesthetic, which combine with γ- Aminobutyric acid-a (GABAA) receptor. Ciprofol has shown equivalent anesthetic efficacy of propofol at 1/4 to 1/5 of the dosage. Ciprofol has the pharmacodynamic characteristics of rapid onset, stable and rapid recovery. Phase III clinical results showed that the incidence of injection pain and respiratory and circulatory depression of ciprofol was lower than that of propofol. Therefore, ciprofol has a good application prospect in the sedation for gastrointestinal endoscopy, especially for overweight and obese patients. We conduct a Multicenter, Randomized, Open-label, Propofol-controlled Study to Evaluate the incidence of hypoxia and severe hypoxia during Gastroenterological Endoscope sedated with CiProfol in Overweight or Obesity patients.

Conditions

Interventions

DRUG

Ciprofol

The sedation of gastrointestinal endoscopy with Ciprofol

DRUG

Propofol

The sedation of gastrointestinal endoscopy with Propofol

Sponsors & Collaborators

  • Zhejiang Tumor Hospital

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Second Hospital of Shanxi Medical University

    collaborator OTHER

  • Dalian Municipal Friendship Hospital

    collaborator UNKNOWN

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Diansan Su · Department of Anesthesiology Renji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-08
Primary Completion
2023-08-15
Completion
2023-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05518929 on ClinicalTrials.gov